Hypothesis

Intermittent, rather than continuous, mTORC1 inhibition triggers a lysosomal cholesterol efflux program that enhances clearance of damaged macromolecules and organelles, converting a compensatory slowdown into a genuine rejuvenation signal.

Mechanistic Rationale

Rapamycin’s canonical effects—reduced protein synthesis, induced autophagy, and FOXO activation—mimic nutrient scarcity and slow damage accumulation. However, lysosomal function is limited not only by autophagosome formation but also by the lipid composition of the lysosomal membrane. Cholesterol accumulation impairs lysosomal acidification and hydrolase activity, creating a bottleneck that prevents effective degradation of ubiquitinated proteins and damaged mitochondria. Recent work shows that mTORC1 inhibition can upregulate the cholesterol transporter NPC1 via a TFEB‑dependent transcriptional program, but only when inhibition is pulsed, allowing periodic reactivation of mTORC1 to reset lysosomal biogenesis. We propose that short rapamycin pulses create a hormetic cycle: during the off‑phase, mTORC1 reactivation drives lysosomal replenishment; during the on‑phase, transient mTORC1 suppression stimulates NPC1‑mediated cholesterol export, restoring lysosomal proteolytic capacity. This cyclic reset enables the autophagic machinery to actually remove existing damage rather than merely slowing its accrual, distinguishing true repair from scarcity mimicry.

Testable Predictions

1. Mice receiving intermittent rapamycin (e.g., 5 days on/2 days off) will show lower lysosomal cholesterol content and higher cathepsin activity in liver and brain compared to continuous dosing or controls, measured via filipin staining and enzymatic assays.
2. The lifespan extension of intermittent rapamycin will exceed that of continuous dosing by at least 15% in C. elegans and will be abolished by NPC1 RNAi, indicating dependence on cholesterol efflux.
3. Transcriptomic profiling will reveal a specific enrichment of lysosomal lipid metabolism genes (NPC1, LAMP2A, MSR1) only during the rapamycin‑off windows, coinciding with peaks in phosphorylated S6K (mTORC1 reactivation).
4. Clearance of pre‑existing damage markers—such as p62‑positive aggregates, mitochondrial ROS, and senescent cell burden (p16^INK4a^)—will be significantly reduced only in the intermittent regimen, despite equivalent overall mTORC1 inhibition as assessed by p‑S6 levels.

Potential Experiments

• Lysosomal Lipidomics: Isolate lysosomes from mouse hepatocytes after 4 weeks of continuous vs. intermittent rapamycin; quantify free cholesterol and cholesteryl esters using LC‑MS/MS.
• Flux Assays: Employ DQ‑BSA and mt‑Keima reporters to monitor autophagic degradation flux in real time across treatment cycles.
• Genetic Dissection: Cross Raptor^f/f^; Alb‑Cre mice with NPC1^+/-^ animals; test whether haploinsufficiency blunts the longevity benefit of intermittent rapamycin.
• Damage Clearance: Use inducible p16‑3MR mice to senescent‑cell burden quantification via bioluminescence before and after treatment regimens.

If intermittent mTORC1 inhibition demonstrably enhances lysosomal cholesterol export and consequently improves the removal of pre‑existing damage, it would reframe rapamycin not as a mere scarcity mimetic but as a periodic reset tool that engages bona fide repair pathways. Failure to observe these changes would support the view that mTOR inhibition primarily acts as a compensatory slowdown without true rejuvenation.